PATENT CLAIM ANALYSIS

Application Number: 15888962
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2019-08
Patent Classification: ["514", "220000"]

Abstract:
The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor.

Claim (Index 8):
The formulation of  claim 7 , wherein the Bromodomain and Extra-Terminal protein inhibitor is JQ1.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 88.0
- Lexical Diversity: 1.24138
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14792490', '14758938', '14811354', '14439127', '15346743']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7495420082616749
- 35 USC 102 Novelty (BERT): 0.5376031580608583
- Combined Prediction Score: 0.7283481232415934
- Mean Citation Score: 340.534594
- Max Citation Score: 375.55722
- Similarity Product: 217.3963226312113

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test